Many transgender men and women seek hormone therapy as part of the transition process. Exogenous testosterone is used in transgender men to induce virilization and suppress feminizing characteristics. In transgender women, exogenous estrogen is used to help feminize patients, and anti-androgens are used as adjuncts to help suppress masculinizing features. Guidelines exist to help providers choose appropriate candidates for hormone therapy, and act as a framework for choosing treatment regimens and managing surveillance in these patients. Cross-sex hormone therapy has been shown to have positive physical and psychological effects on the transitioning individual and is considered a mainstay treatment for many patients.
Social awareness and acceptance of transgender individuals has increased dramatically in the past decade. In the United States, an estimated 0. A transgender person does not have the same gender identity as the sex assigned to them at birth. The term transgender also includes those who have different gender expressions and behaviors than what society expects for their biologic sex. Gender dysphoria is the distress related to sex assigned at birth not matching gender identity. Ways of relieving this distress may vary.
Select PDF you would like to download from the options in the table below:. The SOC are based on the best available science and expert professional consensus. The overall goal of the SOC is to provide clinical guidance for health professionals to assist transsexual, transgender, and gender nonconforming people with safe and effective pathways to achieving lasting personal comfort with their gendered selves, in order to maximize their overall health, psychological well-being, and self-fulfillment.
Transgender people comprise a diverse group of individuals whose gender identity or expression differs from that originally assigned to them at birth. As cross-sex hormones administered for the purposes of gender affirmation may be delivered at high doses and over a period of decades, the carcinogenicity of hormonal therapy in transgender people is an area of considerable concern. In addition, concerns about cancer risk in transgender patients have been linked to sexually transmitted infections, increased exposure to well-known risk factors such as smoking and alcohol use, and the lack of adequate access to screening.